nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA1—renal system—cervical cancer	0.024	0.0511	CbGeAlD
Lithium—IMPA2—uterine cervix—cervical cancer	0.0192	0.041	CbGeAlD
Lithium—IMPA1—female reproductive system—cervical cancer	0.0192	0.041	CbGeAlD
Lithium—GSK3B—epithelium—cervical cancer	0.019	0.0406	CbGeAlD
Lithium—GSK3B—uterine cervix—cervical cancer	0.0189	0.0402	CbGeAlD
Lithium—IMPA2—decidua—cervical cancer	0.0183	0.0391	CbGeAlD
Lithium—IMPA2—renal system—cervical cancer	0.018	0.0384	CbGeAlD
Lithium—GSK3B—decidua—cervical cancer	0.018	0.0383	CbGeAlD
Lithium—GSK3B—renal system—cervical cancer	0.0176	0.0377	CbGeAlD
Lithium—IMPA1—female gonad—cervical cancer	0.0175	0.0373	CbGeAlD
Lithium—IMPA2—endometrium—cervical cancer	0.0174	0.0371	CbGeAlD
Lithium—IMPA2—mammalian vulva—cervical cancer	0.0168	0.0359	CbGeAlD
Lithium—GSK3A—uterine cervix—cervical cancer	0.0164	0.035	CbGeAlD
Lithium—GSK3B—uterus—cervical cancer	0.0157	0.0335	CbGeAlD
Lithium—GSK3A—decidua—cervical cancer	0.0156	0.0333	CbGeAlD
Lithium—GSK3A—renal system—cervical cancer	0.0153	0.0327	CbGeAlD
Lithium—GSK3A—endometrium—cervical cancer	0.0148	0.0317	CbGeAlD
Lithium—IMPA2—female reproductive system—cervical cancer	0.0144	0.0307	CbGeAlD
Lithium—GSK3A—mammalian vulva—cervical cancer	0.0143	0.0306	CbGeAlD
Lithium—GSK3B—female reproductive system—cervical cancer	0.0141	0.0302	CbGeAlD
Lithium—GSK3A—uterus—cervical cancer	0.0137	0.0292	CbGeAlD
Lithium—IMPA2—female gonad—cervical cancer	0.0131	0.028	CbGeAlD
Lithium—IMPA2—vagina—cervical cancer	0.013	0.0278	CbGeAlD
Lithium—GSK3B—female gonad—cervical cancer	0.0129	0.0274	CbGeAlD
Lithium—GSK3B—vagina—cervical cancer	0.0128	0.0273	CbGeAlD
Lithium—GSK3A—female reproductive system—cervical cancer	0.0123	0.0262	CbGeAlD
Lithium—GSK3A—female gonad—cervical cancer	0.0112	0.0239	CbGeAlD
Lithium—GSK3A—vagina—cervical cancer	0.0111	0.0237	CbGeAlD
Lithium—IMPA2—lymph node—cervical cancer	0.00843	0.018	CbGeAlD
Lithium—GSK3B—lymph node—cervical cancer	0.00827	0.0176	CbGeAlD
Lithium—GSK3A—lymph node—cervical cancer	0.00719	0.0153	CbGeAlD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—cervical cancer	0.00119	0.00223	CbGpPWpGaD
Lithium—GSK3A—PI3K/AKT activation—EGFR—cervical cancer	0.00119	0.00223	CbGpPWpGaD
Lithium—GSK3A—GAB1 signalosome—EGFR—cervical cancer	0.00118	0.00222	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—MTOR—cervical cancer	0.00117	0.0022	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—MTOR—cervical cancer	0.00116	0.00219	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—MTOR—cervical cancer	0.00116	0.00218	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—MTOR—cervical cancer	0.00115	0.00217	CbGpPWpGaD
Lithium—GSK3A—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—cervical cancer	0.00115	0.00217	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—MTOR—cervical cancer	0.00115	0.00216	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—FGFR3—cervical cancer	0.00113	0.00213	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—FGFR3—cervical cancer	0.00113	0.00213	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—FGFR3—cervical cancer	0.00113	0.00213	CbGpPWpGaD
Lithium—GSK3B—p53 pathway—TP53—cervical cancer	0.00113	0.00213	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—MTOR—cervical cancer	0.00113	0.00213	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—CASP3—cervical cancer	0.00113	0.00212	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—FGFR3—cervical cancer	0.00112	0.00211	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—STAT3—cervical cancer	0.00112	0.00211	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—FGFR3—cervical cancer	0.00111	0.0021	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—FGFR3—cervical cancer	0.00111	0.00209	CbGpPWpGaD
Lithium—GSK3B—Neural Crest Differentiation—CTNNB1—cervical cancer	0.00111	0.00208	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—CTNNB1—cervical cancer	0.0011	0.00207	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	0.00109	0.00204	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—MTOR—cervical cancer	0.00108	0.00203	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—MTOR—cervical cancer	0.00108	0.00203	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—MTOR—cervical cancer	0.00108	0.00203	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—MTOR—cervical cancer	0.00107	0.00201	CbGpPWpGaD
Lithium—GSK3B—Androgen receptor signaling pathway—STAT3—cervical cancer	0.00107	0.00201	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—MTOR—cervical cancer	0.00106	0.00199	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—MTOR—cervical cancer	0.00106	0.00199	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—FGFR3—cervical cancer	0.00105	0.00197	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—TERT—cervical cancer	0.00105	0.00197	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—FGFR3—cervical cancer	0.00105	0.00197	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—CTNNB1—cervical cancer	0.00104	0.00196	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—TERT—cervical cancer	0.00101	0.00191	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—FGFR3—cervical cancer	0.001	0.00189	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—STAT3—cervical cancer	0.001	0.00188	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—MTOR—cervical cancer	0.000999	0.00188	CbGpPWpGaD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—EGFR—cervical cancer	0.000998	0.00188	CbGpPWpGaD
Lithium—GSK3A—Immune System—UBE3A—cervical cancer	0.000975	0.00184	CbGpPWpGaD
Lithium—GSK3B—Androgen receptor signaling pathway—EGFR—cervical cancer	0.000971	0.00183	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HLA-DPB1—cervical cancer	0.00096	0.00181	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—MTOR—cervical cancer	0.000957	0.0018	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—MTOR—cervical cancer	0.000956	0.0018	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—MTOR—cervical cancer	0.000941	0.00177	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—TERT—cervical cancer	0.00094	0.00177	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000934	0.00176	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—MTOR—cervical cancer	0.000915	0.00172	CbGpPWpGaD
Lithium—GSK3A—Disease—WNT2—cervical cancer	0.000914	0.00172	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—EGFR—cervical cancer	0.000909	0.00171	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—MTOR—cervical cancer	0.000901	0.0017	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.0009	0.00169	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—STAT3—cervical cancer	0.0009	0.00169	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—EGFR—cervical cancer	0.000899	0.00169	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TP53—cervical cancer	0.000897	0.00169	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—EGFR—cervical cancer	0.000877	0.00165	CbGpPWpGaD
Lithium—IMPA2—Metabolism—MTHFR—cervical cancer	0.000874	0.00165	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—EGFR—cervical cancer	0.000871	0.00164	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—TP53—cervical cancer	0.00087	0.00164	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—EGFR—cervical cancer	0.00087	0.00164	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—CASP3—cervical cancer	0.000865	0.00163	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—MTOR—cervical cancer	0.000865	0.00163	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—EGFR—cervical cancer	0.000861	0.00162	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—MTOR—cervical cancer	0.00086	0.00162	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—EGFR—cervical cancer	0.000856	0.00161	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—MTOR—cervical cancer	0.000856	0.00161	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—MTOR—cervical cancer	0.000852	0.0016	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—cervical cancer	0.000851	0.0016	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—MTOR—cervical cancer	0.000848	0.0016	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—MTOR—cervical cancer	0.000835	0.00157	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—STAT3—cervical cancer	0.000834	0.00157	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—CTNNB1—cervical cancer	0.000834	0.00157	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TAAR6—cervical cancer	0.00082	0.00154	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—EGFR—cervical cancer	0.000818	0.00154	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—STAT3—cervical cancer	0.000816	0.00153	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—EGFR—cervical cancer	0.000814	0.00153	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—EGFR—cervical cancer	0.00081	0.00152	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—EGFR—cervical cancer	0.000806	0.00152	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—MTOR—cervical cancer	0.000797	0.0015	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—MTOR—cervical cancer	0.000797	0.0015	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—MTOR—cervical cancer	0.000797	0.0015	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—EGFR—cervical cancer	0.000794	0.00149	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—MTOR—cervical cancer	0.00079	0.00149	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—MTOR—cervical cancer	0.000783	0.00147	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—MTOR—cervical cancer	0.00078	0.00147	CbGpPWpGaD
Lithium—IMPA1—Metabolism—MTHFR—cervical cancer	0.000779	0.00147	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—TERT—cervical cancer	0.000775	0.00146	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—FGFR3—cervical cancer	0.000772	0.00145	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—EGFR—cervical cancer	0.000758	0.00143	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—EGFR—cervical cancer	0.000758	0.00143	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—EGFR—cervical cancer	0.000758	0.00143	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—EGFR—cervical cancer	0.000751	0.00141	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HLA-DQB1—cervical cancer	0.000749	0.00141	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—EGFR—cervical cancer	0.000745	0.0014	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—EGFR—cervical cancer	0.000741	0.0014	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—STAT3—cervical cancer	0.000739	0.00139	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	0.000739	0.00139	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—MTOR—cervical cancer	0.000738	0.00139	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—MTOR—cervical cancer	0.000735	0.00138	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—cervical cancer	0.000731	0.00138	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—TP53—cervical cancer	0.000731	0.00138	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—STAT3—cervical cancer	0.000727	0.00137	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—cervical cancer	0.000723	0.00136	CbGpPWpGaD
Lithium—GSK3B—Immune System—UBE3A—cervical cancer	0.000721	0.00136	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—cervical cancer	0.000714	0.00134	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000713	0.00134	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HLA-DPB1—cervical cancer	0.000709	0.00133	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—MTOR—cervical cancer	0.000706	0.00133	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—EGFR—cervical cancer	0.000702	0.00132	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD8A—cervical cancer	0.0007	0.00132	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—cervical cancer	0.000693	0.0013	CbGpPWpGaD
Lithium—GSK3A—Disease—WNT5A—cervical cancer	0.000693	0.0013	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—CASP3—cervical cancer	0.000676	0.00127	CbGpPWpGaD
Lithium—GSK3B—Disease—WNT2—cervical cancer	0.000675	0.00127	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—EGFR—cervical cancer	0.000672	0.00126	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	0.000671	0.00126	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—CTNNB1—cervical cancer	0.000668	0.00126	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—STAT3—cervical cancer	0.000665	0.00125	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—EGFR—cervical cancer	0.000643	0.00121	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—WNT2—cervical cancer	0.00064	0.0012	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—EGFR—cervical cancer	0.000633	0.00119	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HES1—cervical cancer	0.00062	0.00117	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—STAT3—cervical cancer	0.000616	0.00116	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TAAR6—cervical cancer	0.000606	0.00114	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—EGFR—cervical cancer	0.000604	0.00114	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—STAT3—cervical cancer	0.000603	0.00113	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—EGFR—cervical cancer	0.000601	0.00113	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000599	0.00113	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—CTNNB1—cervical cancer	0.000598	0.00113	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—EGFR—cervical cancer	0.000598	0.00113	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—FGFR3—cervical cancer	0.000596	0.00112	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—EGFR—cervical cancer	0.000595	0.00112	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—EGFR—cervical cancer	0.000587	0.0011	CbGpPWpGaD
Lithium—GSK3A—Immune System—HLA-DPB1—cervical cancer	0.000582	0.0011	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—CTNNB1—cervical cancer	0.000579	0.00109	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—MTOR—cervical cancer	0.000579	0.00109	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—FGFR3—cervical cancer	0.000572	0.00108	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—STAT3—cervical cancer	0.000568	0.00107	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKAP13—cervical cancer	0.000562	0.00106	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—EGFR—cervical cancer	0.00056	0.00105	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—EGFR—cervical cancer	0.00056	0.00105	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—EGFR—cervical cancer	0.00056	0.00105	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—EGFR—cervical cancer	0.000555	0.00104	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HLA-DQB1—cervical cancer	0.000554	0.00104	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—EGFR—cervical cancer	0.00055	0.00104	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—EGFR—cervical cancer	0.000548	0.00103	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	0.000546	0.00103	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—MTOR—cervical cancer	0.000543	0.00102	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—CTNNB1—cervical cancer	0.000538	0.00101	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—EGFR—cervical cancer	0.000529	0.000996	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—EGFR—cervical cancer	0.000518	0.000976	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD8A—cervical cancer	0.000517	0.000973	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—EGFR—cervical cancer	0.000516	0.000972	CbGpPWpGaD
Lithium—GSK3B—Disease—WNT5A—cervical cancer	0.000512	0.000963	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CASP8—cervical cancer	0.00051	0.000959	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—CASP3—cervical cancer	0.0005	0.00094	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	0.000496	0.000934	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—WNT5A—cervical cancer	0.000485	0.000913	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—WNT2—cervical cancer	0.000473	0.00089	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NOTCH1—cervical cancer	0.000468	0.000881	CbGpPWpGaD
Lithium—GSK3A—Immune System—HLA-DQB1—cervical cancer	0.000455	0.000855	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—STAT3—cervical cancer	0.000448	0.000842	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—CTNNB1—cervical cancer	0.000444	0.000835	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—FGFR3—cervical cancer	0.00044	0.000829	CbGpPWpGaD
Lithium—GSK3B—Immune System—HLA-DPB1—cervical cancer	0.00043	0.00081	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—cervical cancer	0.000425	0.000799	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD8A—cervical cancer	0.000424	0.000799	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—FGFR3—cervical cancer	0.000423	0.000796	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—STAT3—cervical cancer	0.00042	0.00079	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—MTOR—cervical cancer	0.000419	0.000789	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CD4—cervical cancer	0.000419	0.000788	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKAP13—cervical cancer	0.000415	0.000781	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—MTOR—cervical cancer	0.000403	0.000758	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD4—cervical cancer	0.000402	0.000756	CbGpPWpGaD
Lithium—GSK3A—Disease—HES1—cervical cancer	0.000399	0.00075	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—EGFR—cervical cancer	0.000382	0.000718	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CASP8—cervical cancer	0.000377	0.000709	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CTNNB1—cervical cancer	0.000372	0.0007	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—WNT5A—cervical cancer	0.000358	0.000675	CbGpPWpGaD
Lithium—GSK3A—Disease—MTHFR—cervical cancer	0.00035	0.000659	CbGpPWpGaD
Lithium—GSK3A—Disease—TERT—cervical cancer	0.000349	0.000657	CbGpPWpGaD
Lithium—GSK3A—Immune System—FGFR3—cervical cancer	0.000347	0.000653	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—cervical cancer	0.000345	0.00065	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—cervical cancer	0.000342	0.000643	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOTCH2—cervical cancer	0.00034	0.000641	CbGpPWpGaD
Lithium—GSK3B—Immune System—HLA-DQB1—cervical cancer	0.000336	0.000632	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CTNNB1—cervical cancer	0.000325	0.000611	CbGpPWpGaD
Lithium—GSK3A—Disease—FGFR3—cervical cancer	0.000321	0.000603	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD8A—cervical cancer	0.000314	0.00059	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CTNNB1—cervical cancer	0.000311	0.000585	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MTOR—cervical cancer	0.00031	0.000583	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CD4—cervical cancer	0.000309	0.000582	CbGpPWpGaD
Lithium—GSK3A—Disease—NOTCH1—cervical cancer	0.000301	0.000566	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—MTOR—cervical cancer	0.000298	0.00056	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD4—cervical cancer	0.000297	0.000559	CbGpPWpGaD
Lithium—GSK3A—Immune System—CASP8—cervical cancer	0.000297	0.000559	CbGpPWpGaD
Lithium—GSK3B—Disease—HES1—cervical cancer	0.000295	0.000554	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—cervical cancer	0.000295	0.000554	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—cervical cancer	0.000283	0.000532	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HES1—cervical cancer	0.000279	0.000525	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CTNNB1—cervical cancer	0.000275	0.000517	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—STAT3—cervical cancer	0.000271	0.00051	CbGpPWpGaD
Lithium—GSK3B—Disease—MTHFR—cervical cancer	0.000259	0.000487	CbGpPWpGaD
Lithium—GSK3B—Disease—TERT—cervical cancer	0.000258	0.000486	CbGpPWpGaD
Lithium—GSK3B—Immune System—FGFR3—cervical cancer	0.000257	0.000483	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOTCH2—cervical cancer	0.000252	0.000473	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—cervical cancer	0.000246	0.000464	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TERT—cervical cancer	0.000245	0.00046	CbGpPWpGaD
Lithium—GSK3A—Immune System—MTOR—cervical cancer	0.000244	0.00046	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD4—cervical cancer	0.000244	0.000459	CbGpPWpGaD
Lithium—GSK3B—Disease—FGFR3—cervical cancer	0.000237	0.000446	CbGpPWpGaD
Lithium—GSK3A—Disease—MTOR—cervical cancer	0.000225	0.000424	CbGpPWpGaD
Lithium—GSK3A—Disease—CD4—cervical cancer	0.000225	0.000424	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FGFR3—cervical cancer	0.000224	0.000422	CbGpPWpGaD
Lithium—GSK3B—Disease—NOTCH1—cervical cancer	0.000222	0.000418	CbGpPWpGaD
Lithium—GSK3B—Immune System—CASP8—cervical cancer	0.000219	0.000413	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—cervical cancer	0.000218	0.00041	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTNNB1—cervical cancer	0.000217	0.000407	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOTCH1—cervical cancer	0.000211	0.000397	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—cervical cancer	0.000209	0.000393	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HES1—cervical cancer	0.000206	0.000388	CbGpPWpGaD
Lithium—GSK3A—Disease—CTNNB1—cervical cancer	0.0002	0.000376	CbGpPWpGaD
Lithium—GSK3A—Immune System—STAT3—cervical cancer	0.000189	0.000355	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TERT—cervical cancer	0.000181	0.00034	CbGpPWpGaD
Lithium—GSK3B—Immune System—MTOR—cervical cancer	0.00018	0.00034	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD4—cervical cancer	0.00018	0.000339	CbGpPWpGaD
Lithium—GSK3A—Disease—STAT3—cervical cancer	0.000174	0.000328	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—cervical cancer	0.000172	0.000323	CbGpPWpGaD
Lithium—GSK3B—Disease—MTOR—cervical cancer	0.000167	0.000314	CbGpPWpGaD
Lithium—GSK3B—Disease—CD4—cervical cancer	0.000166	0.000313	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FGFR3—cervical cancer	0.000166	0.000312	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTNNB1—cervical cancer	0.00016	0.000301	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—cervical cancer	0.000158	0.000298	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MTOR—cervical cancer	0.000158	0.000297	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOTCH1—cervical cancer	0.000156	0.000293	CbGpPWpGaD
Lithium—GSK3B—Disease—CTNNB1—cervical cancer	0.000148	0.000278	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CASP3—cervical cancer	0.000145	0.000273	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNB1—cervical cancer	0.00014	0.000263	CbGpPWpGaD
Lithium—GSK3B—Immune System—STAT3—cervical cancer	0.000139	0.000262	CbGpPWpGaD
Lithium—GSK3B—Disease—STAT3—cervical cancer	0.000129	0.000242	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—cervical cancer	0.000127	0.000239	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STAT3—cervical cancer	0.000122	0.00023	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—cervical cancer	0.000117	0.00022	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MTOR—cervical cancer	0.000117	0.00022	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—cervical cancer	0.000111	0.000209	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP3—cervical cancer	0.000107	0.000202	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNB1—cervical cancer	0.000103	0.000195	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—cervical cancer	9.31e-05	0.000175	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STAT3—cervical cancer	9.02e-05	0.00017	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—cervical cancer	8.2e-05	0.000154	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—cervical cancer	6.88e-05	0.000129	CbGpPWpGaD
